The main market opportunities for PD-L1 x 4-1BB bispecific antibodies lie in their ability to target tumors precisely while minimizing liver toxicity, addressing a gap in cancer therapy. These ...
Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...
Although antibodies to PD-L1 are used in the clinic, their benefit is limited by immune exclusion within the local microenvironment. Objective response rates with anti-PD-L1 monotherapy are low due to ...
Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but ...
The results of a preclinical study have identified a biological mechanism that explains why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors. The study, ...
Functional Characterization and a Real-World Clinical Laboratory Pilot of the Foundation for the National Institutes of Health Circulating Tumor DNA Quality Control Materials A total of 871 patient ...
Predictive value of the triglyceride-glucose index for the efficacy of immunotherapy in patients with advanced NSCLC: A retrospective study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
A PD-L1 score for head and neck cancer helps guide treatment decisions, including when immunotherapy may be used. Here’s what your results mean.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results